# Pharmacokinetics and Safety of WAL2014 (Talsaclidine) Administered Orally to Healthy Adult Male Volunteers

> **NCT02264080** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 12 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** WAL2014
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02264080
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-03
- **Primary completion:** 1999-03
- **Final completion:** —
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2014-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02264080

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02264080, "Pharmacokinetics and Safety of WAL2014 (Talsaclidine) Administered Orally to Healthy Adult Male Volunteers". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02264080. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*